Successful antibody humanization for cervical cancer therapy with improved binding

Turning a lead antibody into a safer candidate powered by AI

Discover how our AI-driven antibody humanization expertise helped a small French biotech reach 80% human sequence homology—making the antibody safer and more market-ready for cervical cancer therapy.

humanization

Complete the form and receive free case report!

This Case Report includes:

  • - A step-by-step humanization workflow combining AI to reduce immunogenicity risk 
  • - Detailed results and variant comparisons, including how lead candidates were selected
  • - 3D structural exploration
  • - Deliverables that accelerate decisions: full report, complete sequence set, and 3 lead candidate samples for next-stage of the project